{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:15Z","timestamp":1792788015071,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T00:00:00Z","timestamp":1542067200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the National Program on Key Research Project of China","award":["2016YFD0500400"],"award-info":[{"award-number":["2016YFD0500400"]}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["31500152"],"award-info":[{"award-number":["31500152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Mega-Project for Infectious Disease","award":["2017ZX10104001-004-001"],"award-info":[{"award-number":["2017ZX10104001-004-001"]}]},{"name":"National Key R&D Program of China","award":["2017YFC1200503"],"award-info":[{"award-number":["2017YFC1200503"]}]},{"name":"National Science and Technology Major Project","award":["2018ZX10201002"],"award-info":[{"award-number":["2018ZX10201002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12985-018-1089-1","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T07:35:01Z","timestamp":1542094501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice"],"prefix":"10.1186","volume":"15","author":[{"given":"Pengcheng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,13]]},"reference":[{"issue":"4","key":"1089_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003709","volume":"9","author":"K Hampson","year":"2015","unstructured":"Hampson K, Coudeville L, Lembo T, Sambo M, Kiefer A, Attlan M, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9(4):e0003709.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"1089_CR2","first-page":"1","volume":"16","author":"S Wang","year":"2010","unstructured":"Wang S. A new PIKA adjuvant rabies vaccine-the therapeutic vaccine for life rescue. J Appl Prev Med. 2010;16(1):1\u20134.","journal-title":"J Appl Prev Med"},{"issue":"44","key":"1089_CR3","doi-asserted-by":"publisher","first-page":"7605","DOI":"10.1016\/j.vaccine.2007.08.054","volume":"25","author":"H Wilde","year":"2007","unstructured":"Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine. 2007;25(44):7605\u20139.","journal-title":"Vaccine"},{"issue":"51","key":"1089_CR4","doi-asserted-by":"publisher","first-page":"7141","DOI":"10.1016\/j.vaccine.2009.09.029","volume":"27","author":"CE Rupprecht","year":"2009","unstructured":"Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Evidence for a 4-dose vaccine schedule for human rabies postexposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009;27(51):7141\u20138.","journal-title":"Vaccine"},{"key":"1089_CR5","unstructured":"Situation of rabies Prev Control in China. Ministry of Health of the People\u2019s Republic of China 2009."},{"key":"1089_CR6","doi-asserted-by":"crossref","unstructured":"Wiktor TH. Virus vaccines and therapeutic approaches. In: Bishop HD, editor. Rhabdomyoviruses, Vol. 3. Boca Raton, FL: CRC Press; 1980. p. 99\u2013112.","DOI":"10.1201\/9781351076401-5"},{"issue":"2","key":"1089_CR7","first-page":"133","volume":"13","author":"H Lin","year":"1999","unstructured":"Lin H, Perrin P. Influence of aluminum adjuvant to experimental rabies vaccine. Chin J Exp Clin Virol. 1999;13(2):133\u20135.","journal-title":"Chin J Exp Clin Virol"},{"issue":"4","key":"1089_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","volume":"10","author":"C Bode","year":"2011","unstructured":"Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccine. 2011;10(4):499\u2013511.","journal-title":"Expert Rev Vaccine"},{"issue":"8","key":"1089_CR9","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/IAI.67.8.3719-3726.1999","volume":"67","author":"KJ Stacey","year":"1999","unstructured":"Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun. 1999;67(8):3719\u201326.","journal-title":"Infect Immun"},{"issue":"14","key":"1089_CR10","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.1128\/JVI.75.14.6482-6491.2001","volume":"75","author":"E Malanch\u00e8re-Br\u00e8s","year":"2001","unstructured":"Malanch\u00e8re-Br\u00e8s E, Payette PJ, Mancini M, Tiollais P, Davis HL, Michel ML. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) or vaccination in HBsAg-transgenic mice. J Virol. 2001;75(14):6482\u201391.","journal-title":"J Virol"},{"issue":"1","key":"1089_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1128\/IAI.74.1.528-536.2006","volume":"74","author":"CP Ivory","year":"2006","unstructured":"Ivory CP, Keller K, Chadee K. CpG-oligodeoxynucleotide is a potent adjuvant with an Entamoeba histolytica gal-inhibitable lectin vaccine against amoebic liver abscess in gerbils. Infect Immun. 2006;74(1):528\u201336.","journal-title":"Infect Immun"},{"issue":"1","key":"1089_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1196\/annals.1348.030","volume":"1082","author":"DM Klinman","year":"2006","unstructured":"Klinman DM, Xie H, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann NYAcad Sci. 2006;1082(1):137\u201350.","journal-title":"Ann NYAcad Sci"},{"issue":"6","key":"1089_CR13","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1189\/jlb.0604330","volume":"77","author":"D Alignani","year":"2005","unstructured":"Alignani D, Maletto B, Liscovsky M, Ropolo A, Moron G, Pistoresi-Palencia MC. Orally administered OVA\/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukoc Biol. 2005;77(6):898\u2013905.","journal-title":"J Leukoc Biol"},{"key":"1089_CR14","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1016\/j.vaccine.2004.01.058","volume":"22","author":"CL Cooper","year":"2004","unstructured":"Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004;22:3136\u201343.","journal-title":"Vaccine"},{"key":"1089_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.vaccine.2008.01.043","volume":"26","author":"W Xueju","year":"2008","unstructured":"Xueju W, Musheng B, Min W, Hongfei W, Li W, Hongtao Y, et al. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine. 2008;26:1893\u2013901.","journal-title":"Vaccine"},{"key":"1089_CR16","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1016\/j.vaccine.2009.12.077","volume":"28","author":"J Ren","year":"2010","unstructured":"Ren J, Sun L, Yang L, Wang H, Wan M, Zhang P, et al. A novel canine favored CpG oligodeoxynucleotide capable of enhancing the efficacy of an inactivated aluminum-adjuvanted rabies vaccine of dog use. Vaccine. 2010;28:2458\u201364.","journal-title":"Vaccine"},{"issue":"2","key":"1089_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. Journal of Basic and Clinical Pharmacy. 2016;7(2):27\u201331.","journal-title":"Journal of Basic and Clinical Pharmacy"},{"key":"1089_CR18","unstructured":"WHO expert consultation on rabies: second report. Geneva: WHO; 2013. WHO-recommended post-exposure prophylaxis regimens, 58,"},{"issue":"1","key":"1089_CR19","first-page":"69","volume":"24","author":"W Xue-ju","year":"2008","unstructured":"Xue-ju W, Jing L, Min W, Li W, Xiuli W, Hongfei W, et al. Determination of optimized MTT colorimetric assay as the identification method for the activity of B type CpG ODN BW006. Chin J Cell Mol Immunol. 2008;24(1):69\u201371.","journal-title":"Chin J Cell Mol Immunol"},{"key":"1089_CR20","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1084\/jem.188.12.2335","volume":"188","author":"S Sun","year":"1998","unstructured":"Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998;188:2335\u201342.","journal-title":"J Exp Med"},{"key":"1089_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","volume":"186","author":"RS Chu","year":"1997","unstructured":"Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper (Th1) immunity. J Exp Med. 1997;186:1623\u201331.","journal-title":"J Exp Med"},{"key":"1089_CR22","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.4049\/jimmunol.161.9.4463","volume":"161","author":"MJ McCluskie","year":"1998","unstructured":"McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998;161:4463\u20136.","journal-title":"J Immunol"},{"issue":"23\u201324","key":"1089_CR23","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1016\/S0264-410X(01)00048-2","volume":"19","author":"C Hunolstein","year":"2001","unstructured":"Hunolstein C, Mariotti S, Teloni R, Alfarone G, Romagnoli G, Orefici G, et al. The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines. Vaccine. 2001;19(23\u201324):3058\u201366.","journal-title":"Vaccine"},{"key":"1089_CR24","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4049\/jimmunol.162.3.1611","volume":"162","author":"J Kovarik","year":"1999","unstructured":"Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert PH, et al. CpG oligonucleotides can cirmcuvent the TH2 polorization of neonatal responses to vaccines but fail to fully redirect TH2 responses established by neonatal priming. J Immunol. 1999;162:1611\u20137.","journal-title":"J Immunol"},{"issue":"13\u201314","key":"1089_CR25","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0264-410X(00)00422-9","volume":"19","author":"JW Eastcott","year":"2001","unstructured":"Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine. 2001;19(13\u201314):1636\u201342.","journal-title":"Vaccine"},{"issue":"8","key":"1089_CR26","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1128\/IAI.69.8.4816-4822.2001","volume":"69","author":"A Al Mariri","year":"2001","unstructured":"Al Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J, et al. Protection of BALB\/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun. 2001;69(8):4816\u201322.","journal-title":"Infect Immun"},{"issue":"2","key":"1089_CR27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/IAI.73.2.828-833.2005","volume":"73","author":"H Xie","year":"2005","unstructured":"Xie H, Gursel I, Ivins BE, Singh M, O'Hagan DT, Ulmer JB, et al. CpG oligodeoxynucleotides adsorbed onto polylactide-co- glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun. 2005;73(2):828\u201333.","journal-title":"Infect Immun"},{"issue":"15","key":"1089_CR28","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1016\/j.vaccine.2006.12.037","volume":"25","author":"CN Fogg","year":"2007","unstructured":"Fogg CN, Americo JL, Lustig S, Huggins JW, Smith SK, Damon I, et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine. 2007;25(15):2787\u201399.","journal-title":"Vaccine"},{"issue":"12\u201313","key":"1089_CR29","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.micinf.2007.08.002","volume":"9","author":"DM Klinman","year":"2007","unstructured":"Klinman DM, Currie D, Lee G, Grippe V, Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect. 2007;9(12\u201313):1478\u201383.","journal-title":"Microbes Infect"},{"issue":"5","key":"1089_CR30","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.4049\/jimmunol.166.5.3451","volume":"166","author":"WS Gallichan","year":"2001","unstructured":"Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001;166(5):3451\u20137.","journal-title":"J Immunol"},{"key":"1089_CR31","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/35047123","volume":"408","author":"H Hemmi","year":"2000","unstructured":"Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740\u20135.","journal-title":"Nature"},{"issue":"6","key":"1089_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1084\/jem.194.6.863","volume":"194","author":"N Kadowaki","year":"2001","unstructured":"Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194(6):863\u20139.","journal-title":"J Exp Med"},{"issue":"10","key":"1089_CR33","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1002\/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H","volume":"31","author":"A Krug","year":"2001","unstructured":"Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001;31(10):3026\u201337.","journal-title":"Eur J Immunol"},{"issue":"8","key":"1089_CR34","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.4049\/jimmunol.166.8.5000","volume":"166","author":"M Bauer","year":"2001","unstructured":"Bauer M, Redecke V, Ellwart JW, Rothenfusser S, Hornung V, Bals R, et al. Bacterial CpG DNA triggers activation and maturation of human CD11c (\u2212), CD123(+) dendritic cells. J Immunol. 2001;166(8):5000\u20137.","journal-title":"J Immunol"},{"key":"1089_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/374546a0","volume":"374","author":"AM Krieg","year":"1995","unstructured":"Krieg AM, Yi A, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374:546\u20138.","journal-title":"Nature"},{"issue":"6","key":"1089_CR36","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1189\/jlb.1202630","volume":"73","author":"JD Marshall","year":"2003","unstructured":"Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol. 2003;73(6):781\u201392.","journal-title":"J Leukoc Biol"},{"key":"1089_CR37","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.157.5.1840","volume":"157","author":"ZK Ballas","year":"1996","unstructured":"Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157:1840\u20137.","journal-title":"J Immunol"},{"key":"1089_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1006\/cimm.1996.0009","volume":"167","author":"MD Halpern","year":"1996","unstructured":"Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-g production by stimulation of IL-12 and tumor necrosis factor-a. Cell Immunol. 1996;167:72\u20138.","journal-title":"Cell Immunol"},{"issue":"1","key":"1089_CR39","first-page":"43","volume":"17","author":"HL Xu","year":"2001","unstructured":"Xu HL, Wang SQ, Wang SF, Guo F, Lu RJ, Li R. Evaluation of Immunostimulatory activities of human CpG-ODN containing 5\u2019-GTCGTT-3\u2019 motif in murine model. Chinese Journal of Virology. 2001;17(1):43\u20137.","journal-title":"Chinese Journal of Virology"},{"issue":"6","key":"1089_CR40","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","volume":"24","author":"CL Cooper","year":"2004","unstructured":"Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-BHBV vaccine in healthy adults: a double-blind phase I\/II study [J]. J Clin Immunol. 2004;24(6):693\u2013701.","journal-title":"J Clin Immunol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-1089-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-018-1089-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-018-1089-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T21:30:48Z","timestamp":1694035848000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-018-1089-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1186\/s12985-018-1089-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,13]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The program for immunization of HDCV combined with CpG ODN was approved (approval NO. 201510140028) by the Ethical Committee of the National Institute of Viral Disease Control and Prevention, China CDC. Animal care and use protocol in this study abided \u201cThe Guidance on Treating Experimental Animals\u201d which promulgated by the ministry of science and technology of China. No non-human primates were used in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"174"}}